1. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
- Author
-
Garrido, Pilar, Hladun, R., de Álava, Enrique, Álvarez, R., Bautista, F., López-Ríos, F., Colomer, Ramon, Rojo, F., Universitat Autònoma de Barcelona, Sociedad Española de Oncología Médica, Sociedad Española de Anatomía Patológica, Sociedad Española de Hematología y Oncología Pediátricas, Bayer, Roche, UAM. Departamento de Medicina, Institut Català de la Salut, [Garrido P] Sociedad Española de Oncología Médica (SEOM), Departamento de Oncología Médica, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, CIBERONC, Madrid, Spain. [Hladun R] Sociedad Española de Hematología y Oncologías Pediátricas (SEHOP). Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [de Álava E] Sociedad Española de Anatomía Patológica (SEAP), Departamento de Citología e Histología Normal y Patológica, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), CSIC, Facultad de Medicina, Universidad de Sevilla, CIBERONC, Sevilla, Spain. [Álvarez R] Sociedad Española de Oncología Médica (SEOM), Departamento de Oncología Médica, Hospital Universitario Gregorio Marañón. Instituto Investigación Sanitaria Gregorio Marañon (IISGM), Madrid, Spain. [Bautista F] Sociedad Española de Hematología y Oncologías Pediátricas (SEHOP), Oncología Pediátrica, Departamento de Hematología y Trasplante de Células Madre Hematopoyéticas, Hospital Universitario Infantil Niño Jesús, Madrid, Spain. [López-Ríos F] Sociedad Española de Anatomía Patológica (SEAP), Departamento de Patología, Laboratorio de Dianas Terapéuticas, Hospital Universitario HM Sanchinarro, CIBERONC, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus, and Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica
- Subjects
Oncology ,Cancer Research ,Oncogene Proteins, Fusion ,Paediatric haematology ,Entrectinib ,Molecular oncology ,Càncer - Diagnòstic - Espanya ,Neoplasms ,Tyrosine Receptor Kinase ,Other subheadings::/diagnosis [Other subheadings] ,Medicine ,Molecular Targeted Therapy ,Child ,In Situ Hybridization, Fluorescence ,Societies, Medical ,Membrane Glycoproteins ,Reverse Transcriptase Polymerase Chain Reaction ,Age Factors ,High-Throughput Nucleotide Sequencing ,General Medicine ,Pathological anatomy ,Immunohistochemistry ,Psychological Phenomena::Mental Processes::Thinking::Decision Making::Consensus [PSYCHIATRY AND PSYCHOLOGY] ,Geographic Locations::Europe::Spain [GEOGRAPHICALS] ,Càncer - Tractament - Espanya ,Benzamides ,fenómenos psicológicos::procesos mentales::pensamiento::toma de decisión::consenso [PSIQUIATRÍA Y PSICOLOGÍA] ,Mutations ,Adult ,medicine.medical_specialty ,Consensus ,Indazoles ,Medicina ,Otros calificadores::/diagnóstico [Otros calificadores] ,Oncologia - Presa de decisions - Espanya ,neoplasias [ENFERMEDADES] ,Special Article ,Internal medicine ,Humans ,Receptor, trkB ,Receptor, trkC ,Target therapy ,Receptor, trkA ,Gene ,Protein Kinase Inhibitors ,localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS] ,Gene fusions ,business.industry ,Public health care ,Neoplasms [DISEASES] ,Pyrimidines ,Spain ,Pyrazoles ,Neoplasm ,business ,Target therapies - Abstract
The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical management of patients presenting with tumours with these alterations. Tumours that harbour NTRK fusions are found in both adults and children; and they are either rare tumours with common NTRK fusions that may be diagnostic, or more prevalent tumours with rare NTRK fusions. To assess currently available evidence on this matter, three key Spanish medical societies (the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Pathological Anatomy (SEAP), and the Spanish Society of Paediatric Haematology and Oncology (SEHOP) have brought together a group of experts to develop a consensus document that includes guidelines on the diagnostic, clinical, and therapeutic aspects of NTRK-fusion tumours. This document also discusses the challenges related to the routine detection of these genetic alterations in a mostly public Health Care System., SEOM, SEAP and SEHOP have received financial support for this project in the form of unrestricted collaboration in the logistics of expert meeting from Bayer and Roche.
- Published
- 2021